{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.464","value":"0.00"},{"groupId":"OG001","spread":"18.895","value":"5.56"},{"groupId":"OG002","spread":"19.621","value":"6.86"},{"groupId":"OG003","spread":"17.670","value":"0.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"52"}],"units":"Participants"}],"title":"Cycle 2 Day 1 (C2D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.267","value":"11.26"},{"groupId":"OG001","spread":"21.717","value":"5.30"},{"groupId":"OG002","spread":"20.655","value":"15.28"},{"groupId":"OG003","spread":"15.680","value":"3.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"43"}],"units":"Participants"}],"title":"C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.069","value":"6.25"},{"groupId":"OG001","spread":"19.585","value":"8.76"},{"groupId":"OG002","spread":"22.539","value":"13.51"},{"groupId":"OG003","spread":"15.099","value":"4.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"38"}],"units":"Participants"}],"title":"C4D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.316","value":"4.17"},{"groupId":"OG001","spread":"21.246","value":"8.33"},{"groupId":"OG002","spread":"21.466","value":"13.27"},{"groupId":"OG003","spread":"18.774","value":"5.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"36"}],"units":"Participants"}],"title":"C5D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.437","value":"5.11"},{"groupId":"OG001","spread":"28.118","value":"5.68"},{"groupId":"OG002","spread":"24.521","value":"12.18"},{"groupId":"OG003","spread":"21.599","value":"0.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"33"}],"units":"Participants"}],"title":"C6D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.676","value":"6.51"},{"groupId":"OG001","spread":"22.393","value":"9.17"},{"groupId":"OG002","spread":"23.659","value":"22.22"},{"groupId":"OG003","spread":"18.598","value":"4.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"15"}],"units":"Participants"}],"title":"C7D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.080","value":"4.60"},{"groupId":"OG001","spread":"21.425","value":"10.10"},{"groupId":"OG002","spread":"19.816","value":"30.30"},{"groupId":"OG003","spread":"25.158","value":"5.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"}],"units":"Participants"}],"title":"C8D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.938","value":"6.09"},{"groupId":"OG001","spread":"26.199","value":"6.61"},{"groupId":"OG002","spread":"24.470","value":"26.67"},{"groupId":"OG003","spread":"20.543","value":"7.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"title":"C9D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.844","value":"12.04"},{"groupId":"OG001","spread":"26.064","value":"13.77"},{"groupId":"OG002","spread":"13.889","value":"28.70"},{"groupId":"OG003","spread":"22.923","value":"5.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"title":"C10D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.186","value":"10.33"},{"groupId":"OG001","spread":"22.603","value":"11.40"},{"groupId":"OG002","spread":"14.407","value":"32.50"},{"groupId":"OG003","spread":"19.444","value":"14.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"title":"C11D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.388","value":"8.33"},{"groupId":"OG001","spread":"24.494","value":"12.75"},{"groupId":"OG002","spread":"16.667","value":"27.78"},{"groupId":"OG003","spread":"26.021","value":"2.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"title":"C12D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"54"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 (\"very poor\") to 7 (\"excellent\"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received cemiplimab 3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks (Q2W) during each 8-week treatment cycle, for up to 96 weeks (12 cycles).","id":"OG000","title":"Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W"},{"description":"Participants received cemiplimab 3 mg/kg IV Q2W during each 8-week treatment cycle, for up to 96 weeks (12 cycles).","id":"OG001","title":"Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W"},{"description":"Participants received cemiplimab 350 mg IV every 3 weeks (Q3W) during each 9-week treatment cycle, for up to 54 weeks (6 cycles).","id":"OG002","title":"Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W"},{"description":"Participants received cemiplimab 600 mg IV every 4 weeks (Q4W) during each 8-week treatment cycle, for up to 48 weeks (6 cycles).","id":"OG003","title":"Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W"}],"paramType":"MEAN","populationDescription":"The FAS included all enrolled participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure and \"Number Analyzed\" is the number evaluable at each time point. Only Groups 1, 2, 3, and 4 were planned for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline, Up to Cycle 12 Day 1 (Week 89)","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}